ABSTRACT
Objective To investigate the effects of atorvastatin and trimetazidine treatment of coronary heart disease (CHD) effect and influence on blood lipid levels.Methods Selected 103 CHD patients treated in our hospital from March 2013 to January 2016, were randomly divided into observation group (n=57) and control group (n=46), the observation group was given atorvastatin combined with trimetazidinetreatment, control group was given trimetazidine treatment, compared the two groupstherapeutic, blood lipid levels etc.Results The curative effect of observation group was significantly better than that of the control group ( P <0.05 ) , markedly effective was 54.39%, effective was 38.60%; The observation group after treatment blood lipid levels were lower than before treatment ( P <0.05 ); The control group after treatmenttotal cholesterol ( TC ) and low density lipoprotein cholesterol (LDL-C) compared with before treatment decreased (P<0.05), and three glycerol (TG) and high density lipoprotein cholesterol ( HDL-C) difference had no statistical significant compared with before treatment;The observation group after treatment TC, TG, HDL-C and LDL-C were lower than the control group (P<0.05);Observation group after treatment the duration of exercise, induced angina pectoris attack time and ST segment down 1 mm time were (624.59 ±90.15)s, (470.29 ±44.20)s and (455.04 ±82.05)s, significantly longer than that in control group (P<0.05);Observation group after treatment superoxide dismutase (SOD) was (87.82 ±8.84)U/mL, significantly higher than that of the control group (P<0.05), and malondialdehyde (MDA)was (4.02 ±0.70)nmol/mL, was significantly lower than that of the control group (P<0.05).Conclusion Atorvastatin combined with trimetazidine treatment CHD curative effect is better, can reduce the level of blood lipid and oxidative stress, is worthy of clinical use.
ABSTRACT
Objective To investigate the change of serum CD62p of coronary heart disease (CHD) patients after different doses of clopidogrel administration.Methods One hundred and ninety-one patients with CHD were selected as our subjects.Of which,95 cases were with SAP and 66 cases were with non ST segment elevation acute coronary syndrome (NST-ACS).SAP patients were randomly given clopidogrel at dose of 75 mg/d or 150 mg/d and served as A and B groups.NST-ACS patients were randomly given 300 mg clopidogrel,then randomly divided into C and D groups with sequentially taking clopidogrel at dose of 75 mg/d or 150 mg/d respectively.Thirty healthy peoples were served as E group without drug intervention.Concentrations of serum CD62p were detected by Elisa before taking clopidogrel,24 h and the fifty day of after taking clopidogrel.Results (1) Before taking clopidogrel,the serum concentrations of CD62p in CHD patients were higher (A group:(7.62 ± 2.99) ng/L,B group:(8.48 ± 3.13) ng/L,C group:(9.50 ± 3.32) ng/L,D group:(10.22 ± 5.14) ng/L than that of healthy control group ((5.49 ± 1.99) ng/L,P ＜ 0.05).The Serum CD62p levels in SAP patients were lower than that of NST-ACS patients (P ＜ 0.05).(2)The serum concentrations of CD62p in A and B groups at before taking clopidogrel were (7.62 ±2.99) ng/L and (8.48 ±3.13) ng/L respectively,higher than that four days after taking clopidogrel ((6.79 ± 2.51) ng/L,(6.37 ± 1.80) ng/L;t =2.390,4.520;P ＜0.05 or P ＜0.01).There was no statistical significant difference between A and B groups(P ＞0.05).(3) In C and D groups,the serum CD62p at before taking clopidogrel were (9.50 ±3.32) ng/L and (10.22 ±5.14) ng/L,higher than that after taking clopidogrel for four days ((8.21 ± 2.62) ng/L,(8.17 ± 2.37) ng/L; t =2.084,2.157 ; P ＜ 0.05).No significant difference was seen between C and D groups (P ＞ 0.05).Conclusion The serum CD62p in patients with CHD was higher than that in the healthy control.Clopidogrel administration can decrease serum CD62p in CHD patients.
ABSTRACT
Objective To evaluate the changes of platelet activity before and after anti-platelet treatment in pa?tients with coronary heart disease, and their responsiveness to clopidogrel through detecting the phosphorylation levels of va?sodilator stimulated phosphoprotein (VASP). Methods Twenty-eight cases of healthy people were selected as control group . Patients with chronic stable angina pectoris (CSA, n=95) were randomly divided into A (48 cases) group and B (47 cases) group,and were given clopidogrel 75 mg/d or 150 mg/d respectively;Patients with non ST segment elevation acute coronary syndrome (NST-ACS, n=67) were all given 300 mg loading dose of clopidogrel at the first time, then randomly divid?ed into C (33 cases) group and D (34 cases) group, and given clopidogrel 75 mg/d and 150 mg/d respectively. Blood were tak?en to examine the phosphorylation levels of serum VASP by ELISA before taking clopidogrel, at time point of loading dose and the fifth day of clopidogrel administration . Results Before treatment, phosphorylation levels of serum VASP were low?er in A, B, C, D groups than those in the normal control group(P0.05).②In group C and group D, phosphorylation levels of serum VASP were significantly increased at loading dose and the fifth day of clopidogrel administration than those before treatment (P 0.05). Conclusion The phosphorylation level of serum VASP was lower in patients with coronary heart disease than that in normal control group. Clopidogrel can improve the phosphorylation level of serum VASP in NST-ACS patients .